This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (27)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in this journal  Topic Collections  • Schizophrenia  • Randomized Controlled Trial  • Alert me on articles by topic

A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

Arch Gen Psychiatry. 2006;63:1069-1072.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Despite schizophrenia's longstanding affliction of humankind,¹ effective treatments for this debilitating disorder only became available in the middle of the 20th century.² Numerous, now landmark, studies^3-5 demonstrated incontrovertibly that chlorpromazine, the prototypic antipsychotic, was more effective than nonpharmacologic treatment (eg, placebo, psychotherapy) in alleviating the acute symptoms of schizophrenia and preventing their recurrence. Although many effective antipsychotics have been introduced in the wake of chlorpromazine, the pace of real progress through drug development and innovation has been arduous and slow.

Any doubts about this unfortunate reality should be eliminated by the results described in Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1),^6-7 which are virtually identical to those described previously from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).^8-9 These studies found few differences in effectiveness between first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) in nonrefractory patients—a conclusion that runs counter to the impressions of many clinicians . . . [Full Text of this Article]

AUTHOR INFORMATION
Jeffrey A. Lieberman, MD

RELATED LETTERS

First- and Second-Generation Antipsychotics: Learning From CUtLASS and CATIE
Rajiv Tandon, William T. Carpenter, and John M. Davis
Arch Gen Psychiatry. 2007;64(8):977-978.
EXTRACT | FULL TEXT  

CUtLASS Confirms CATIE
Jim Mintz and Alex Kopelowicz
Arch Gen Psychiatry. 2007;64(8):978.
EXTRACT | FULL TEXT  

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia—Reply
Peter B. Jones, Thomas R. E. Barnes, Peter Elton, Linda Davies, Graham Dunn, Helen Lloyd, Karen P. Hayhurst, Robin M. Murray, Alison Marwick, and Shôn Lewis
Arch Gen Psychiatry. 2007;64(8):979-980.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Robert A. Rosenheck
Arch Gen Psychiatry. 2006;63(10):1074-1076.
EXTRACT | FULL TEXT  

Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Peter B. Jones, Thomas R. E. Barnes, Linda Davies, Graham Dunn, Helen Lloyd, Karen P. Hayhurst, Robin M. Murray, Alison Markwick, and Shôn W. Lewis
Arch Gen Psychiatry. 2006;63(10):1079-1087.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Who Are the New Users of Antipsychotic Medications?
Domino and Swartz
Psychiatr. Serv. 2008;59:507-514.
ABSTRACT | FULL TEXT  

Experience of VA Psychiatrists With Pharmaceutical Detailing of Antipsychotic Medications
Sernyak and Rosenheck
Psychiatr. Serv. 2007;58:1292-1296.
ABSTRACT | FULL TEXT  

First- and Second-Generation Antipsychotics: Learning From CUtLASS and CATIE
Tandon et al.
Arch Gen Psychiatry 2007;64:977-978.
FULL TEXT  

CUtLASS Confirms CATIE
Mintz and Kopelowicz
Arch Gen Psychiatry 2007;64:978-978.
FULL TEXT  

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia Reply
Jones et al.
Arch Gen Psychiatry 2007;64:979-980.
FULL TEXT  

Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy
Davies et al.
Br. J. Psychiatry 2007;191:14-22.
ABSTRACT | FULL TEXT  

Furor Therapeuticus: Benjamin Rush and the Philadelphia Yellow Fever Epidemic of 1793
Eisenberg
Am. J. Psychiatry 2007;164:552-555.
FULL TEXT  

Outcomes similar with first- and second-generation antipsychotics
Seidlinger
Am J Health Syst Pharm 2006;63:2172-2175.
FULL TEXT  

Bibliography PSYCHOPHARMACOLOGY
Focus 2006;4:512.
FULL TEXT